1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
ConvaTec Group Plc

ConvaTec Group Plc

CTEC.L
ConvaTec Group PlcGB flagLondon Stock Exchange
220.20
GBp
-3.00
- -
4.29BMarket Cap
ConvaTec Group Plc
CTEC.L
(London Stock Exchange)

Recent

price

220.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.87
0.89
0.85
1.23
0.9
0.94
0.93
0.95
1.01
1.02
1.05
1.12
1.2
Revenue per Share
0.01
-0.07
-0.05
-0.15
0.08
0.11
- -
0.06
0.06
0.03
0.06
0.09
0.09
Basic EPS, GAAP
0.1
0.05
0.03
0.01
0.11
0.14
0.17
0.16
0.11
0.07
0.12
0.13
0.14
Free Cash Flow per Basic Share
0.45
- -
- -
- -
0.01
0.04
0.04
0.03
0.04
0.04
0.05
0.06
0.07
Dividend per Share
0.02
-0.05
-1.17
-1.75
-0.31
-0.26
-0.31
-0.3
-0.3
-0.32
-0.31
-0.28
-0.27
Book Value per Share
-1.66
-1.59
-1.52
-0.87
-0.53
-0.39
-0.31
-0.21
-0.18
-0.27
-0.27
-0.2
-0.24
Tangible Book Value per Share
1,951
1,951
1,951
1,376
1,951
1,956
1,971
1,992
2,009
2,024
2,039
2,048
2,025
Basic Weighted Avg Shares
1,701
1,734
1,650
1,688
1,765
1,832
1,827
1,894
2,038
2,072
2,142
2,289
2,439
Sales/Revenue/Turnover
18.09
12.62
13.96
9.12
14.04
14.61
5.3
11.14
9.99
10.67
12.38
14.5
15.83
Operating Margin (%)
189
192
181
182
179
190
210
198
211
209
215
221
224
Depreciation Expense
15
-127
-93
-203
158
222
10
112
118
63
130
191
175
Net Income, GAAP
67.52
- -
- -
- -
3.6
- -
48.15
35.6
22.27
23.2
22.16
22.36
23.91
Effective Tax Rate (%)
0.89
-7.33
-5.66
-12.01
8.98
12.1
0.54
5.94
5.77
3.03
6.08
8.34
7.18
Profit Margin (%)
464
416
472
471
537
572
571
665
542
356
334
282
324
Working Capital
3,722
3,534
3,477
1,737
1,745
1,582
1,515
1,442
1,271
1,280
1,292
1,180
1,492
LT Debt
48
-222
-219
1,246
1,524
1,617
1,561
1,671
1,695
1,610
1,693
1,689
1,518
Total Equity
- -
- -
- -
- -
7.55
- -
1.56
4.23
4.93
5.6
6.99
8.73
9.81
Return on Invested Capital (%)
- -
- -
- -
- -
74.56
- -
4.06
14.69
16.29
13.43
28.09
38.22
27.75
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-64.64%
-1.75%
-10.12%
Free Cash Flow
304.44%
4.97%
3.64%
Net Income, GAAP
103.47%
20.67%
-8.38%
Sales/Revenue/Turnover
4.01%
5.21%
6.55%
Total Cash Common Dividend
- -
17.97%
7.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,142
2024
- -
- -
- -
- -
2,289
2025
- -
- -
- -
- -
2,439

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.06
2024
- -
- -
- -
- -
0.09
2025
- -
- -
- -
- -
0.09

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.05
2024
- -
- -
- -
- -
0.06
2025
- -
- -
- -
- -
0.07
Similar Companies
Bioteque Corporation (4107.TWO)
American Medical Technologies Inc. (ADLI)
Earum Pharmaceuticals Limited (EARUM.BO)
Psykey, Inc. (CEOS)
Sartorius AG (SRT.DE)
Elegance Optical International Holdings Limited (0907.HK)
Business
ConvaTec Group Plc develops, manufactures and markets medical products and technologies focused on managing chronic conditions including advanced wound care, ostomy care, continence and critical care, and infusion care; its portfolio encompasses advanced wound dressings and technologies for acute and chronic wounds from conditions such as diabetes, traumatic injury and burns; ostomy pouches, devices, accessories and personalized services for stoma patients ensuring comfort, security and skin protection; continence catheters and critical care solutions for urinary continence and patient dignity; and disposable infusion sets for insulin pump therapy in diabetes management, pain management and other therapies including partnerships with Medtronic's 780G extended wear infusion set, Tandem Mobi, Beta Bionics iLet and AbbVie's Parkinson's Neria Guard. The company operates in over 100 countries with primary markets in North America and Europe; employs approximately 10,000 people; was founded in 1978 as part of E.R. Squibb & Sons and is headquartered at 20 Eastbourne Terrace, London, England, United Kingdom. Recent developments include four key product launches or major geographic expansions in 2024 such as ConvaFoam, Esteem Body, GentleCath Air for Women and extended wear infusion sets; three acquisitions related to its Livramedom home services group in 2024 plus one small acquisition in France alongside approximately $90 million in earn-outs; increased R&D investment to 4.6% of sales and $122 million in capital expenditures emphasizing clinical and regulatory engagement; divestiture of low-margin hospital care, industrial sales and Russia operations completed by early 2025; and progression of seven additional products for launch in 2025 and 2026 including support for Mitsubishi Tanabe launches and diversification beyond diabetes.

Company News

APIChatGPT

  • gurufocus.com

    Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

  • proactiveinvestors.com

    FTSE 100 Live: London stocks pare gains; US futures point to mixed start

  • proactiveinvestors.com

    FTSE 100 Live: London stocks off to a strong start after Dow hits new record